1044800

Atracurium besylate

United States Pharmacopeia (USP) Reference Standard

• Synonym(s): 2,2′-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium]dibenzenesulfonate, BW-33A, Tracrium
• Empirical Formula (Hill Notation): C₆₅H₈₂N₂O₁₈S₂
• CAS Number: 64228-81-5
• Molecular Weight: 1243.48
• MDL number: MFCD00797403
• UNSPSC Code: 41116107
• PubChem Substance ID: 329749081
• NACRES: NA.24

Properties

• grade: pharmaceutical primary standard
• API family: atracurium
• manufacturer/tradename: USP
• application(s): pharmaceutical (small molecule)
• format: neat
• storage temp.: 2-8°C
• SMILES string: [O-]S(=O)(=O)c1ccccc1.[O-]S(=O)(=O)c2ccccc2.COc3ccc(CC4c5cc(OC)c(OC)cc5CC[N+]4(C)CCC(=O)OCCCCCOC(=O)CC[N+]6(C)CCc7cc(OC)c(OC)cc7C6Cc8ccc(OC)c(OC)c8)cc3OC
• InChI: 1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2
• InChI key: XXZSQOVSEBAPGS-UHFFFAOYSA-L
• Gene Information: human ... CHRNA1(1134) , CHRNB1(1140) , CHRND(1144) , CHRNE(1145) , CHRNG(1146)

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

• The feasibility of the posterior tibial nerve-flexor hallucis brevis pathway applied in neuromuscular monitoring: This multicentric, controlled, and prospective clinical trial investigates a new method for neuromuscular monitoring using Atracurium besylate, providing insights into improving surgical anesthesia practices (Chen et al., 2024).


• Onset and duration of action of escalating doses of atracurium in anesthetized healthy goats: This study assesses the pharmacokinetics and pharmacodynamics of Atracurium besylate in veterinary medicine, highlighting its efficacy and safety in non-human subjects, which is crucial for translating findings to human clinical settings (Ishihara et al., 2024).


• Under-dosing and over-dosing of neuromuscular blocking drugs and reversal agents: beware of the risks: This editorial discusses the critical balance required in dosing Atracurium besylate to optimize patient outcomes and minimize side effects in surgical settings, emphasizing the importance of precise dosing for effective neuromuscular blockade (Hunter and Blobner, 2024).


• Comparison of the Onset of Action, Maintenance, and Recovery of Three Weight-based Dosing of Cisatracurium in Patients with Morbid Obesity in Laparoscopic Bariatric Surgery: Although focused on Cisatracurium, this study provides comparative insights that could be applicable to similar studies on Atracurium besylate, particularly in terms of dose adjustment for specific patient populations undergoing surgical procedures (Rokhtabnak et al., 2023).


• Neuromuscular Blockade: This piece provides a broad overview of neuromuscular blocking agents like Atracurium besylate, discussing their mechanisms and applications in clinical anesthesia, which is essential for understanding the full scope of these drugs′ utility in medical practice (Cook and Simons, 2024).

Biochem/physiol Actions

Nicotinic acetylcholine receptor antagonist.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Safety Information

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable